Friday, May 02, 2014 4:11:11 PM
Unless SEC rules have changed over the years, there was not a requirement for a Q report but I have not looked at such things for well over 10 years.
Why would they wish to hold off on Q1 earnings report?
Unless the company went to hell in a hand basket over the hold on a phase II trial and everyone went on vacation, there should be many things to update investors about. Admit that is an assumption on my part but I do assume Halo is moving ahead with the short and long term business plan. I do expect Halo to be very careful and precise in what they say.
I do not expect the phase II PAG trial to restart. Halo now has access to all the data that they would not have without the hold. That data will be used to help determine path forward. The phase II SWOG trial could resume since they were still recruiting the 30 patient 1B run in safety phase.
Insiders in Halo are restricted to a sales plan window. If memory serves, this was put in place around 5 years ago.
Good Luck,
Rod
Why would they wish to hold off on Q1 earnings report?
Unless the company went to hell in a hand basket over the hold on a phase II trial and everyone went on vacation, there should be many things to update investors about. Admit that is an assumption on my part but I do assume Halo is moving ahead with the short and long term business plan. I do expect Halo to be very careful and precise in what they say.
I do not expect the phase II PAG trial to restart. Halo now has access to all the data that they would not have without the hold. That data will be used to help determine path forward. The phase II SWOG trial could resume since they were still recruiting the 30 patient 1B run in safety phase.
Insiders in Halo are restricted to a sales plan window. If memory serves, this was put in place around 5 years ago.
Good Luck,
Rod
Never argue with a fool, for after awhile, it becomes difficult to determine which is the fool.
Recent HALO News
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/15/2026 08:13:30 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/11/2026 08:10:16 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/11/2026 08:09:29 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/11/2026 08:06:06 PM
- HALOZYME REPORTS FIRST QUARTER 2026 RESULTS AND REITERATES 2026 FINANCIAL GUIDANCE • PR Newswire (US) • 05/11/2026 08:01:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/07/2026 11:04:36 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/07/2026 11:04:01 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/07/2026 11:03:43 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/07/2026 11:02:55 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/07/2026 11:02:11 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/07/2026 11:01:36 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/07/2026 08:16:24 PM
- Halozyme Announces Global Collaboration and License Agreement with GSK to Develop Subcutaneous Formulations of Multiple Promising Oncology Targets • PR Newswire (US) • 05/07/2026 01:00:00 PM
- Halozyme and Oruka Announce Global Collaboration and License Agreement to Develop ORKA-001 with Hypercon™ Technology • PR Newswire (US) • 05/06/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/05/2026 09:05:10 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/01/2026 08:45:44 PM
- Halozyme to Report First Quarter 2026 Financial and Operating Results • PR Newswire (US) • 04/30/2026 08:30:00 PM
- Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors • Edgar (US Regulatory) • 04/30/2026 02:39:50 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/30/2026 12:12:51 PM
- Halozyme Appoints Darren Snellgrove as Chief Financial Officer • PR Newswire (US) • 04/30/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/24/2026 08:06:24 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/07/2026 09:13:42 PM
- Halozyme signs licensing deal with Vertex for drug delivery technology • IH Market News • 04/07/2026 02:11:29 PM
- Halozyme Announces Global Collaboration and License Agreement with Vertex Pharmaceuticals for Hypercon™ Technology • PR Newswire (US) • 04/07/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 10:29:18 PM
